NEUCHATEL, Switzerland--(BUSINESS WIRE)--Mar. 20, 2017--
Masimo (NASDAQ:
MASI) announced today the CE marking of noninvasive blood pressure
(NIBP) measurements for the Rad-97™ Pulse CO-Oximeter® and
connectivity hub. Rad-97 offers Measure-through Motion and Low
Perfusion™ SET® pulse oximetry and upgradeable rainbow®
noninvasive blood constituent monitoring technology in a compact
standalone monitor configuration which can also collect and remotely
transmit data from connected devices.
This Smart News Release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20170320005410/en/
Masimo Rad-97™ Pulse CO-Oximeter® and Connectivity Hub with Noninvasive Blood Pressure (Photo: Business Wire)
Rad-97 with NIBP enables clinicians to measure arterial blood pressure
for adult, pediatric, and neonatal patients, with three measurement
modes: spot-check, automatic interval (which measures blood pressure
routinely, at a desired interval), and stat interval (which continually
measures blood pressure for a desired duration). An integrated port
allows clinicians to connect a blood pressure cuff inflation hose
directly to Rad-97, and is compatible with both disposable and reusable
cuffs, for a variety of patient types, designed for reliability and
patient comfort.
With the addition of NIBP to Rad-97, clinicians can easily and
automatically chart blood pressure data directly from the same
monitoring device that measures oxygen saturation, total hemoglobin, and
other noninvasive parameters. In hospital settings and when used in
conjunction with Masimo Iris Gateway™ or Patient SafetyNet™*, data from
Rad-97 and other devices connected via the Iris™ hub can be sent
directly to the patient’s electronic medical record (EMR). With Patient
SafetyNet, alarms and alerts from connected devices are seamlessly
forwarded to clinicians.
Rad-97 includes built-in wireless connectivity, via Wi-Fi and Bluetooth®.
Using Bluetooth or a wired USB connection, Rad-97 can connect to nearby
devices, such as glucometers and weight scales, and can allow the data
from the connected device to be transmitted remotely. Rad-97 will be
available for use on home and enterprise networks to connect to remote
monitoring systems, including Patient SafetyNet. Additional devices can
be simultaneously attached to Rad-97 using the Iris hub.
Rad-97 features a high-resolution, 1080p HD color display with
user-friendly multi-touch navigation, allowing clinicians to easily
customize the device to best suit their monitoring and viewing needs.
Users can also rapidly configure the device to accommodate different
patient populations using customizable profiles. A rechargeable battery
lasting seven hours allows Rad-97 to be used in situations where
portability or extended operation without access to power are needed. An
optional roll stand allows for tetherless device transport, offering
additional flexibility when space is limited.
Rad-97 will also be available with an optional camera, which can be used
in conjunction with Masimo Patient SafetyNet. The camera will provide a
high resolution, high-frame rate video feed, as well as audio, to the
Patient SafetyNet view-station. When used at home, camera-equipped
Rad-97 will allow patients and clinicians to interact remotely, making
it well-suited as a point-of-care device for potential telehealth
applications.
Like Radical-7®, Rad-97 features Measure-through Motion and
Low Perfusion pulse oximetry (SpO2), pulse rate (PR), and
perfusion index (PI). Clinicians can add other monitoring solutions such
as the rainbow SET™ measurements PVi®, total hemoglobin (SpHb®),
methemoglobin (SpMet®), acoustic respiration rate (RRa®),
carboxyhemoglobin (SpCO®), and oxygen content (SpOC™).
Additional parameters such as Oxygen Reserve Index™ (ORi™) and
respiration rate from the pleth (RRp™) are also available, making Rad-97
the smallest Masimo bedside device currently capable of monitoring the
full rainbow SET platform.
“Rad-97 brings our core SET® and rainbow®
technologies to a compact design, which allows broader applications in
many new settings, including the home, with its hub and telepresence
capabilities,” said Joe Kiani, Founder and CEO of Masimo. “We’re excited
to extend its range of possibilities with the addition of integrated
blood pressure measurement.”
Rad-97 is not available in the United States.
@MasimoInnovates |
#Masimo
*The use of the trademark Patient SafetyNet is under license from
University HealthSystem Consortium.
About Masimo
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive
monitoring technologies. Our mission is to improve patient outcomes and
reduce the cost of care by taking noninvasive monitoring to new sites
and applications. In 1995, the company debuted Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry, which has been
shown in multiple studies to significantly reduce false alarms and
accurately monitor for true alarms. Masimo SET® has also been
shown to help clinicians reduce severe retinopathy of prematurity in
neonates,1 improve CCHD screening in newborns,2
and, when used for continuous monitoring in post-surgical wards, reduce
rapid response activations and costs.3,4,5 Masimo SET®
is estimated to be used on more than 100 million patients in leading
hospitals and other healthcare settings around the world. In 2005,
Masimo introduced rainbow® Pulse CO-Oximetry technology,
allowing noninvasive and continuous monitoring of blood constituents
that previously could only be measured invasively, including total
hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin
(SpCO®), methemoglobin (SpMet®), and more
recently, Pleth Variability Index (PVi®) and Oxygen Reserve
Index (ORi™), in addition to SpO2, pulse rate, and perfusion
index (PI). In studies with SpHb, reductions in blood transfusion*were
observed,6,7 and when used with PVi, a reduction in 30-day
mortality was observed.8 In 2014, Masimo introduced Root®,
an intuitive patient monitoring and connectivity platform with the
Masimo Open Connect™ (MOC-9™) interface, enabling other companies to
augment Root with new features and measurement capabilities. Masimo is
also taking an active leadership role in mHealth with products such as
the Radius-7™ wearable patient monitor, iSpO2®
pulse oximeter for smartphones, and the MightySat™ fingertip pulse
oximeter. Additional information about Masimo and its products may be
found at www.masimo.com.
Published clinical studies on Masimo products can be found at http://www.masimo.com/cpub/clinical-evidence.htm.
*Clinical decisions regarding red blood cell transfusions should be
based on the clinician’s judgment considering, among other factors:
patient condition, continuous SpHb monitoring, and laboratory diagnostic
tests using blood samples.
References
-
Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm
Infants through Changes in Clinical Practice and SpO2
Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
-
de-Wahl Granelli A et al. Impact of pulse oximetry screening on the
detection of duct dependent congenital heart disease: a Swedish
prospective screening study in 39,821 newborns. BMJ. 2009;338.
-
Taenzer AH et al. Impact of Pulse Oximetry Surveillance on Rescue
Events and Intensive Care Unit Transfers: A Before-And-After
Concurrence Study. Anesthesiology. 2010; 112(2):282-287.
-
Taenzer AH et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia
Patient Safety Foundation Newsletter. Spring-Summer 2012.
-
McGrath SP et al. Surveillance Monitoring Management for General Care
Units: Strategy, Design, and Implementation. The Joint Commission
Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
-
Ehrenfeld JM et al. Continuous Non-invasive Hemoglobin Monitoring
during Orthopedia Surgery: A Randomized Trial. J Blood Disorders
Transf. 2014. 5:9. 2.
-
Awada WN et al. Continuous and noninvasive hemoglobin monitoring
reduces red blood cell transfusion during neurosurgery: a prospective
cohort study. J Clin Monit Comput. 2015 Feb 4.
-
Nathan N et al. Impact of Continuous Perioperative SpHb Monitoring.
Proceedings from the 2016 ASA Annual Meeting, Chicago. Abstract #A1103.
Forward-Looking Statements
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, among others, statements regarding the potential
effectiveness of Masimo Rad-97™ Pulse CO-Oximeter® with
Noninvasive Blood Pressure. These forward-looking statements are based
on current expectations about future events affecting us and are subject
to risks and uncertainties, all of which are difficult to predict and
many of which are beyond our control and could cause our actual results
to differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors,
including, but not limited to: risks related to our assumptions
regarding the repeatability of clinical results; risks related to our
belief that Masimo's unique noninvasive measurement technologies,
including Masimo Rad-97 Pulse CO-Oximeter with Noninvasive Blood
Pressure, contribute to positive clinical outcomes and patient safety;
as well as other factors discussed in the "Risk Factors" section of our
most recent reports filed with the Securities and Exchange Commission
("SEC"), which may be obtained for free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included
in this press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or
clarify these statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under
the applicable securities laws.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170320005410/en/
Source: Masimo
Masimo
Evan Lamb, 949-396-3376
elamb@masimo.com